Lv21
120 积分 2026-07-05 加入
Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study
6小时前
待确认
GPCR drug discovery: new agents, targets and indications
8天前
已完结
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs
9天前
已完结
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
3个月前
已完结
Vitamin E for people with non-alcoholic fatty liver disease
3个月前
已完结
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
3个月前
已完结
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
3个月前
已完结
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
3个月前
已完结
皖公网安备34019202002308
